title: Possible autocrine/paracrine actions of insulin-like growth factors during embryonic development: expression and action of IGFs in undifferentiated P19 cells.
abstract: The insulin-like growth factors I and II (IGF I and II) and their cell surface receptors are expressed in the mammalian embryo and may function as autocrine or paracrine growth factors during early development. P19 embryonic carcinoma cells, derived from a 7.5 day mouse embryo, were used as a model for a functional study of the IGF system in post-implantation embryogenesis. Undifferentiated P19 cells synthesized IGF I and II, the type I and II IGF receptors, and IGF binding proteins (IGF BP2, IGF BP3, and IGF BP4). P19 cells showed an increase in thymidine incorporation of 150% of control with a 4 hour incubation of IGF I (10 ng/ml) or IGF II (100 ng/ml) and an increase in cell viability compared to control cells during 24 hours of serum starvation. In both experiments IGF I was more potent than IGF II. Endogenous concentrations of IGF I and II in conditioned media were low compared to the doses of exogenous IGFs required for biologic effect, but nonetheless contributed significantly to baseline DNA synthesis, as demonstrated by inhibition of IGF actions with specific antibodies. Cell surface associated IGF BPs bound more radiolabeled IGF than IGF receptors, as determined by binding studies and affinity cross-linking. IGF I and IGF II appeared to regulate production of IGF BP2, suggesting that the IGFs may regulate their own actions by altering the abundance of their binding proteins.
authors.affiliation: Department of Pediatrics, University of North Carolina, Chapel Hill.
authors.forename: D J
authors.initials: DJ
authors.lastname: Eicher
authors.forename: B M
authors.initials: BM
authors.lastname: Moats-Staats
authors.forename: A D
authors.initials: AD
authors.lastname: Stiles
authors.forename: A J
authors.initials: AJ
authors.lastname: D'Ercole
mesh_terms: D000818:Animals; D002454:Cell Differentiation; D002455:Cell Division; D002460:Cell Line; D002470:Cell Survival / Q000187:drug effects; D004247:DNA / Q000096:biosynthesis; D015342:DNA Probes; D004261:DNA Replication / Q000187:drug effects; D004622:Embryo, Mammalian; D007334:Insulin-Like Growth Factor I / Q000096:biosynthesis* / Q000494:pharmacology*; D007335:Insulin-Like Growth Factor II / Q000096:biosynthesis* / Q000494:pharmacology*; D051379:Mice; D009838:Oligodeoxyribonucleotides; D016133:Polymerase Chain Reaction; D012333:RNA, Messenger / Q000096:biosynthesis*; D017526:Receptor, IGF Type 1 / Q000096:biosynthesis*; D017527:Receptor, IGF Type 2 / Q000096:biosynthesis*; D013724:Teratoma; D013936:Thymidine / Q000378:metabolism; D014316:Tritium
chemical_list: D015342:DNA Probes; D009838:Oligodeoxyribonucleotides; D012333:RNA, Messenger; D017527:Receptor, IGF Type 2; D014316:Tritium; D007334:Insulin-Like Growth Factor I; D007335:Insulin-Like Growth Factor II; D004247:DNA; D017526:Receptor, IGF Type 1; D013936:Thymidine